|
|
|
This International Women’s Day, we honor the remarkable women who educate, innovate, and inspire across the fields of urology and oncology. Through UroToday–GU Oncology Today®, we celebrate the many physician-scientists, clinicians, researchers, and healthcare professionals whose contributions continue to shape patient care and advance the science.
While we feature just a few of these outstanding women here, we extend our gratitude to all women in healthcare who lead with expertise, compassion, and vision—your work makes a lasting impact every day.
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
| peer-to-peer |
|
|
|
|
|
|
|
|
Multidisciplinary Care, Early Detection, and Ongoing Prostate Cancer Challenges
|
|
Maha Hussain, MD, FACP, FASCO
|
| Maha Hussain speaks with Phillip Koo about advances in prostate cancer diagnostics and therapeutics. Dr. Hussain emphasizes critical unmet needs including better understanding of resistance mechanisms, detection of micrometastatic disease, and equitable access to care, noting that early detection and follow-up remain essential for optimal outcomes.
|
|
|
|
|
|
|
|
|
|
|
|
|
Considerations for Patient Selection and Imaging in PSMA-Targeted Therapy
|
Tanya Dorff, MD, and Julie Graff, MD
Neeraj Agarwal speaks with Tanya Dorff and Julie Graff about the practical challenges in radioligand therapy management. The conversation reveals significant variability in real-world practice, particularly around imaging strategies for lutetium therapy monitoring.
|
|
|
|
|
|
|
|
|
|
|
|
Conducting Clinical Trials in a Rapidly Evolving Treatment Landscape
|
|
Andrea Apolo, MD
|
| Ashish Kamat interviews Andrea Apolo to discuss her panel at the BCAN Think Tank on lessons learned from bladder cancer clinical trials. Dr. Apolo led a multidisciplinary session titled featuring perspectives from surgeons, medical oncologists, and patient advocates.
|
|
|
|
|
|
|
|
|
|
|
|
|
Radiopharmaceutical Therapies: Safety, Education, and Collaboration in Oncology
|
Heather Jacene, MD, and Neha Vapiwala, MD, FACR, FASTRO, FASCO
Phillip Koo moderates a conversation between Neha Vapiwala and Heather Jacene (SNMMI vice president-elect) about advancing radiopharmaceutical therapy through interdisciplinary cooperation. Both societies are heavily investing in RPT education, with ASTRO
|
|
|
|
|
|
|
|
|
 |
|
| Multi-Center Study Examines Protein Biomarkers in Upper Tract Cancer Detection |
| Jennifer Linehan, MD |
| Jennifer Linehan discusses the Oncuria-Detect multiplex urine test for upper tract urothelial carcinoma across seven centers with 120 patients. Clinical applications include surveillance combined with imaging to reduce unnecessary ureteroscopies and identifying BCG-resistant bladder cancer patients. |
|
|
|
|
|
|
|
|
|
|
|
Confronting the Persistent Gap Between Training and Leadership for Women in Healthcare
|
Aparna Kamat, MD, and Shilpa Gupta, MD
Aparna Kamat introduces Invoke Potential, addressing women's underrepresentation in medical leadership despite equal or greater medical school enrollment. The initiative focuses on negotiation skills, mentorship, sponsorship, and work-life equity.
|
|
|
|
|
|
|
|
|
|
|
|
Developing a Patient-Centered Decision Aid for Urinary Diversion Choices in Bladder Cancer
|
|
Divya Ajay, MD, MPH
|
| Divya Ajay discusses a patient-centered decision aid for urinary diversion selection developed through BCAN's Young Investigator Award. The team conducted three rounds of semi-structured interviews with 22 patients, four caregivers, and 23 physicians.
|
|
|
|
|
|
|
|
|
|
|
|
|
ctDNA to Guide Response-Adapted Bladder Preservation in MIBC: Investigating a Strategy from the Integrated RETAIN Trials Analysis
|
Pooja Ghatalia, MD, and Elizabeth Plimack, MD, MS, FASCO
Pooja Ghatalia discusses pooled ctDNA analysis from the RETAIN-1 and RETAIN-2 trials involving 111 muscle-invasive bladder cancer patients. RETAIN-2 enrolled clinical T2-T3 N0 M0 patients receiving three cycles of dose-dense MVAC plus nivolumab.
|
|
|
|
|
|
|
|
|
|
|
|
STAMPEDE Trial Biomarker Analysis for Advanced Prostate Cancer Treatment
|
Emily Grist, MD, MRCP, PhD, and Andrea Miyahira, PhD
Emily Grist presents STAMPEDE trial transcriptome analysis of 1,523 patients randomized to docetaxel or abiraterone comparisons. Decipher score was strongly prognostic across metastatic and non-metastatic disease.
|
|
|
|
|
|
|
|
|
|
|
|
CISTO Study: Patient Preferences Drive Bladder Cancer Treatment Choice, Shaping Quality of Life Outcomes
|
|
Angie Smith, MD, MS
|
| Angela Smith presents CISTO trial patient preference analysis with Sam Chang. The pragmatic study enrolled patients with recurrent high-grade NMIBC choosing bladder-sparing therapy or radical cystectomy.
|
|
|
|
|
|
|
|
|
|
|
|
|
Design and Safety of a Patient-Centric Expanded Access Program with Cretostimogene Grenadenorepvec
|
|
Sarah Psutka, MD, MS, FACS
|
| Sarah Psutka discusses cretostimogene grenadenorepvec expanded access program with Ashish Kamat. The replicative oncolytic immunotherapy achieved 76% complete response rate in BOND-003 with duration exceeding two years in BCG-unresponsive NMIBC with CIS.
|
|
|
|
|
|
|
|
|
|
|
|
|
Mechanisms, Side Effects, and Decision-Making for OAB Medications
|
|
Ariana Smith, MD
|
| Ariana Smith discusses oral pharmacotherapy for overactive bladder with Alan Wein. The 2024 SUFU/AUA guidelines recommend antimuscarinics and beta-3 agonists with grade A evidence.
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostic Algorithm and Treatment Resources for Chronic Pelvic Pain
|
|
Elise De, MD
|
| Elise De speaks with Alan Wein about surgical management of pelvic pain from an AUA workshop. Dr. De emphasizes that history provides diagnosis 70% of the time.
|
|
|
|
|
|
|
|
|
|
|
|
|
Final Analysis of Phase 3 POTOMAC Study in High-Risk NMIBC
|
|
Maria De Santis, MD, PhD
|
| Maria De Santis speaks with Ashish Kamat about the POTOMAC trial results presented at ESMO. The phase 3 study randomized 1,018 BCG-naive high-risk NMIBC patients to durvalumab plus BCG induction and maintenance, durvalumab plus BCG induction only, or BCG alone.
|
|
|
|
|
|
|
|
|
|
|
|
|
Re-Induction Nadofaragene in BCG-Unresponsive NMIBC: Real-World Multicenter Experience
|
|
Bogdana Schmidt, MD, MPH
|
| Bogdana Schmidt joins Ashish Kamat to discuss real-world experience with re-induction of nadofaragene firadenovec in BCG-unresponsive NMIBC. Across multiple centers, re-induction showed meaningful activity, particularly in papillary-only disease, and appeared safe, with low progression signals over early follow-up.
|
|
|
|
|
|
|
|
|
|
|
|
|
Enfortumab Vedotin and Pembrolizumab in Practice: A Case Study in Metastatic Urothelial Carcinoma
|
|
Brenda Martone, MSN, ANP-BC, AOCNP
|
| Brenda Martone joins Alicia Morgans to discuss a case study of a 79-year-old patient treated with enfortumab vedotin and pembrolizumab following the EV-302 regimen for metastatic urothelial carcinoma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
